System for dosed distribution
SUBSTANCE: systems and methods for controlled dosage of a composition comprising sodium diclofenac contained in a dispensing distribution system are provided. The method includes pressing of a manual pump to dispense a dose of a topical anaesthetic in a viscous solution where the manual pump is configured to dispense a dose within the tolerance indicated by the appropriate instruction approved by the government regulatory authority and topical solution distribution over the skin.
EFFECT: systems and method allow to treat the signs and symptoms of osteoarthritis.
12 cl, 5 dwg, 6 tbl, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition for control of pain accompanying individual's joint diseases containing hyaluronic acid, which is cross-linked by cycling a double bond in a group of cinnamic acid in partially amidated hyaluronic acid presented by formula (1) to form a cyclobutane cycle, wherein in the above formula, Ar represents a phenyl group, n is equal to an integer 2 or 3; HA represents a carboxy residue of hyaluronic acid, and m represents a relation of amidation of hyaluronic acid to all the carboxyl groups and is equal to 3-50% in relation to all the carboxyl groups, and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition represents a product for injection, wherein the pharmaceutical composition represents the product for injection, wherein the amount of the cross-linked hyaluronic acid makes 1 wt % at the total amount of the product for injection, wherein a single dose of the product for injection makes 2-3 ml, wherein the pharmaceutical composition represents a single-use preparation, which is administered every 13 weeks and more.
EFFECT: invention provides the extremely long analgesic action after the single administration, earlier onset of the analgesic action.
15 cl, 1 dwg, 5 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutical compositions for the combined therapy of arthropathies, except for rheumatoid arthritis, degenerative disk diseases, joint pains and/or autoimmune disease (particularly alopecia, neurodermitis). There are presented: a pharmaceutical composition for the above application containing a glucocorticoid, exosomes prepared of autologous blood and a cytokine antagonist ortokin or anakinra; a method for producing it involving the pharmaceutical composition containing the exosomes prepared of autologous blood and the cytokine antagonist ortokin or anakinra, and the pharmaceutical composition containing the glucocorticoid and the cytokine antagonist ortokin or anakinra, and versions of using the above substances for producing the pharmaceutical composition for the combined therapy.
EFFECT: technical effect consists in achieving the synergetic effect both on the exposure rate and remote outcomes of the specified diseases with reducing side effects of the glucocorticoid (cortisone).
33 cl, 1 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical composition, containing compound of formula or for prevention or treatment of diseases, associated with oxidative stress, selected from group, consisting of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke episodes), MERRF syndrome (myoclonic epilepsy with ragged red fibres) or Kearns-Sayre syndrome, arrhythmia, cardioplegia or myocardium infarction. in formula (1) na stands for 1 or 2, Aa represents 5-membered heteroaryl or heterocycle, each of which has 2 heteroatoms, selected from N, O and S, Rla represents R5a-Xa-Ba-X′a-, Ba represents direct bond, Xa and X′a independently on each other represent direct bond or -OC(O)-, R5a represents hydrogen or 6-9-membered monocyclic or condensed cyclic heterocycle or heteroaryl, each of which has from 1 to 3 heteroatoms, selected from N, O and S, and is optionally substituted with oxo or C1-C6-alkyl, R2a represents -(CR8aR9a)pa-Ya-R7a , pa stands for number from 0 or 1, Ya represents direct bond or -O-, R7a represents hydrogen or phenyl, R3a, R8a, R9a, R10a represent hydrogen, R4a represents -(CH2)pa-Da-R10a-, Da represents C5-cycloalkyl or 6-membered heterocycle, which has 1 heteroatom, selected from N, S and O. Radical values for formula (2) are give in invention formula.
EFFECT: obtaining compositions for prevention or treatment of diseases, associated with oxidative stress.
19 dwg, 5 tbl, 3 ex
SUBSTANCE: invention refers to medicine, namely to rheumatology, and can be used in treating patients suffering from rheumatoid arthritis. The method involves prescribing methotrexat 15 mg a week per os, folic acid 5 mg a week per os, movalis 15 mg a day per os. If the patient has the second degree of activity of rheumatoid arthritis, IL-1β of 1.3±0.3 pg/ml and more, IL-6 of 1.5±0.3 pg/ml and more, TNF-α of 1.78±0.35 pg/ml and more, IL-4 of 3.7±0.34 pg/ml and less, leptine of 6.4±0.42 pg/ml and more, glycosaminoglycans of 0.310±0.032 g/l, 7 daily procedures of intravenous laser exposure are prescribed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes. If observing the third degree of activity, IL-1β of 2.01±0.18 pg/ml and more, IL-6 of 3.01±0.38 pg/ml and more, TNF-α of 3.3±0.25 pg/ml and more, IL-4 of 1.3±0.24 pg/ml and less, leptine of 8.8±0.72 pg/ml and more, glycosaminoglycans of 1.3±0.54 g/l, 10 daily procedures are performed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5-2.0 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes.
EFFECT: method enables reducing a rate of aggravations, an intensity of clinical manifestations, drug load on the patient, prolonging remissions ensured by a normalising effect on cytokine dynamics - reduced pro-inflammatory and increased anti-inflammatory cytokines.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compound, represented by the following formula
or its pharmaceutically acceptable salt. In claimed formula each symbol has values, determined in formula of invention. Versions of formula [I] compound and particular compounds are also objects of invention. In addition, invention relates to pharmaceutical composition, ITK inhibitor and means for treatment or prevention of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection and other diseases and methods of treating said diseases.
EFFECT: claimed compounds inhibit induced T-cellular kinase (ITK).
32 cl, 86 tbl, 387 ex
SUBSTANCE: group of inventions refers to medicine, and concerns using a human Annexin-1 antibody (Anx-A1), which has the sequence SEQ ID NO: 23 for treating a disease caused by abnormal T-cell activation. The group of inventions also concerns a method of treating a disease caused by abnormal T-cell activation, involving administering a therapeutic amount of the above antibody into an individual in need thereof; using the above antibody for producing a therapeutic agent for treating a disease caused by abnormal T-cell activation.
EFFECT: group of inventions provides treating the disease caused by abnormal T-cell activation.
9 cl, 11 ex, 22 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound of formula , which is a methylhydrofumarate (MHF) prodrug. In formula (I), radicals and symbols have the values specified in the patent claim. The invention also refers to a pharmaceutical composition containing the declared methylhydrofumarate drugs, to using the declared methylhydrofumarate drugs and the pharmaceutical composition containing them, for treating diseases, such as psoriasis, asthma, multiple sclerosis, inflammatory intestinal disease and arthritis, and to a method of treating the above diseases.
EFFECT: higher oral bioavailability and plasma MHF, dimethylfumarate and/or other metabolites.
47 cl, 1 tbl, 54 ex
SUBSTANCE: as medications administered are: methotrexate 15 mg per week intake, folic acid 5 mg per week intake, movalis 15 mg per day intake. Laser therapy is administered in differential way depending on degree of disease activity and level of glucosaminoglycanes (GAG). In case of second stage of rheumatoid arthritis - index DAS28 3.2-5.1, level of glucosaminoglycanes 0.510±0.032 g/l, 7 daily procedures of intravenous laser irradiation are carried out. Radiating head KL-VLOK with wavelength 635 nm, power at the end of disposable light guide 1.5 mW, exposure time 15 minutes and laser head KL-VLOK-365 with wavelength 365 nm, power at the end of light guide 1.0 mW, exposure time 5 minutes, are alternated. In case of third degree of activity index DAS28 is higher than 5.1, GAG level is equal or is higher than 0.618±0.069 g/l, 10 procedures are carried out Radiating head KL-VLOK with wavelength 635 nm, power at outlet of disposable light guide 1.5-2.0 mW, exposure time 15 minutes and laser head KL-VLOK-365 nm, power at outlet of disposable light guide 1.0 mW, time of exposure 5 minutes.
EFFECT: method makes it possible to reduce frequency of exacerbations, reduce expression of clinical manifestations, reduce drug load on patient, provides earlier arrest of disease symptoms due to differentiated approach in case of administration of intravenous laser irradiation of blood and its normalising action on GAG indices and reduction of disease activity degree.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel N-containing heteroaryl derivatives of formula I or II or their pharmaceutically acceptable salts, which possess properties of JAK kinase, in particular JAK3, and can be applied for treating such diseases as asthma and chronic obstructive pulmonary disease (COPD). In formulae A represents carbon and B represents nitrogen or A represents nitrogen and B represents carbon; W represents CH or N; R1 and R2, independently represent hydrogen, C1-4alkyl, halogenC1-4alkyl, -CN; R3 represents C1-4alkyl, R9-C1-4alkyl, Cy1, where Cy1 is optionally substituted with one or several substituents R10; R4 represents hydrogen, C1-4alkyl, R12R7N-C0alkyl, where one of R7 and R12 represents hydrogen, and the other represents C1-4alkyl or group R13, which is selected from C1-5alkyl, Cy2-C0alkyl; R5 represents hydrogen; R6 represents hydrogen, C1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl, R12R7N-C1-4alkyl, R16CO-C0alkyl, Cy1; R7 represents hydrogen or C1-4alkyl; R9 represents halogen, -CN, -CONR7R12, -COR13, CO2R12, -OR12, -SO2R13, -SO2NR7R12, -NR7R12, -NR7COR12; R10 represents C1-4alkyl or R9-C0-4alkyl; R11 represents C1-4alkyl, halogen, -CN, -NR7R14; R12 represents hydrogen or R13; R13 represents C1-5alkyl, hydroxyC1-4alkyl, cyanoC1-4alkyl, Cy2-C0alkyl or R14R7N-C1-4alkyl; where Cy2 is optionally substituted with one or several constituents R11; R14 represents hydrogen or C1-4alkyl; R16 represents C1-4alkyl, halogenC1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl or cyanoC1-4alkyl; Cy1 represents monocyclic carbocyclic unsaturated or saturated ring, selected from C3-C6cycloalkyl, phenyl, or saturated monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or partially unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available C atom, and where one or several ring C or S atoms are optionally oxidised with formation of CO or SO2; and Cy2 represents monocyclic carbocyclic unsaturated ring, selected from C3-C6cycloalkyl, or aromatic monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available atom C or N.
EFFECT: obtaining novel heteroaryl derivatives.
27 cl, 41 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: pharmaceutical composition in the form of a tablet with an erodible matrix, which contains one or more fumaric acid ethers, as well as a rate-controlling agent, representing hydroxypropylcellulose and a binding agent, representing lactose, with the decomposition of the said degradable matrix providing the controlled release of the said fumaric acid ether (ethers).
EFFECT: provision of the controlled release of fumaric acid ether (ethers).
19 cl, 43 ex, 2 tbl, 2 dwg
SUBSTANCE: invention relates to medical equipment, namely to devices and systems for the supply of medical fluid media into a target region, in particular to surgical or haemostatic supplying instruments, which contain a plastic part, which can be bent into a required shape and held in it. A supplying device for the supply of a substance into the target region contains a formable tip, made with a possibility for a fluid medium to pass through it and containing the distal terminal part and the proximal terminal part, made with a possibility of connection with at least one reservoir for the fluid medium. The formable tip is also made with a possibility of its formation into a required shape and cutting to a required length by ordinary dressing scissors. The formable tip additionally contains a formable or a plastic tube, which contains a cavity for the transfer of the substance and at least one cavity, placing a plastic element. The plastic element is made of a soft metal, sufficiently strong for supporting the required shape after bending and at the same time sufficiently soft and weak to provide a possibility of its cutting by ordinary dressing or similar scissors. The plastic element represents an aluminium wire, passing in fact in the direction, parallel to the longitudinal direction of the said tubular element.
EFFECT: invention is made with a possibility of being cut to a required length by means of dressing scissors and simultaneously possesses sufficient strength to provide the required keeping of the formable tip in the required shape.
15 cl, 12 dwg
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for the treatment of local skin I-II degree radioreactions on irradiation fields after neutron therapy in patients with head and neck malignancies. For this purpose the applications of ozonised sunflower oil with peroxide number 18% and acid number 71 mg KON/g are performed on the area of the affected skin. The impact is performed after a session of neutron therapy 1-2 times per day for 4-5 days.
EFFECT: method ensures the reduction of the number of radioreactions and skin injuries due to optimally selected parameters of the applied medication, capable of the fast arrest of pain syndrome, reduction of oedema of surrounding tissues, wound-healing action in specific irradiation conditions.
4 dwg, 1 ex
SUBSTANCE: method involves taking general baths and prescribing mud applications on lower extremities with underlying standard drug therapy. The patient takes prepared silicate-carbonate baths with the concentration of sodium salt of metasilicic acid of 100-150 mg/l and the content of carbon dioxide of 1.2 g/l. The bath water temperature is 36°-37°C. The length of the procedure is 10-15 minutes. Taking the baths is followed by having a 30-40-minute rest. Sulphide silt mud sock- or boot-like applications are performed. The mud temperature is 32°-36°C; the length of procedure is 8-20 minutes. The procedures are performed 2 days running, with a pause on the 3rd day. The therapeutic course makes 6-10 procedures.
EFFECT: method provides the further development of the symptom-free involvement of target organs: heart, kidneys, vessels by taking the antihypertensive, antianginal and antiarrhythmic effects, promotes the energetic and adaptation possibilities of the body.
SUBSTANCE: method involves doing therapeutic exercises and pulsed ultrasonic therapy at a pulse length of 10 ms. That is combined with the magnetic stimulation of the shoulder girdle muscles: m. trapezius m. deltoideus, m. supraspinatus, m. infraspinatus on the involved side. That involves the exposure in accordance with a stable technique with using paired pulses of the length of 220±20 mcs at a pulse repetition frequency of 25±5 pulse/min and a pulse-to-pulse spacing of 80 ms for 3 min per one field. The exposure intensity is 70-90% of the maximum magnetic induction amplitude 1,300 mT. The total length of the procedure is 12 minutes. Then 30 minutes later, mud therapy is conducted by applications on the involved shoulder joint. A mud cake temperature makes 38-40 degrees, and the length of the exposure makes 20 minutes. The mud therapy is followed by ultrasonic therapy. The exposure covers the rotator cuff and attachment points of the tendons - m. supraspinatus, m. infraspinatus, m. teres minor on the involved side. The exposure follows a labile technique at an intensity of 0.2-0.4 W/cm2 for 2 minutes per each field at the total length of the procedure of 8 minutes. The procedures are daily. The therapeutic course is 8-10 procedures.
EFFECT: method enables clinical effectiveness by recovering the motor activity of the involved extremity and prolongs the remission, prevents the progression of the biomechanical and neurodystrophic disorders, and formation of neurological complications.
1 ex, 4 tbl, 1 dwg
SUBSTANCE: invention refers to medicine, namely to neurology, physiotherapy. A method involves a manual therapy, therapeutic exercises, a balneotherapy; cream containing iodide-bromide ingredients is applied on the skin in a projection of a trigger point and compressed by kneading circular motions. That is followed by manipulations on muscles by doing therapeutic exercises. Doing the therapeutic exercises involves using the techniques for postisometric relaxation for tensed muscles, and for reinforcing of the weak muscles. The balneotherapy is ensured by taking A.S. Zalmanov's turpentine baths.
EFFECT: method reduces the length of treatment by the exposure on the trigger points prolonging the myofascial pain, extends the range of patients without regard to the skin type, including children and adolescents.
4 cl, 2 ex
SUBSTANCE: liquid applicator comprises a handle, a base and an applicator pad. The handle has proximal and distal ends and comprises a receiver and an elastic cap. The receiver is configured to enclose a package comprising liquid, and to facilitate the liquid removal from the package. The elastic cap is configured to close the package tightly and to deflect under an external pressure, providing thereby applying the external pressure to the package if the latter arranged inside the receiver, to compress the package and to ensure bleeding. The base projects in the radial direction to the outside at a non-zero angle from the distal end of the handle. The base is configured to guide the liquid flow and comprises a distal hole and an outer wall projecting in a transverse direction to the outside from the base and arranged circumferentially about the distal hole. The pad is attached to the base hydraulically connected to an inner portion of the receiver. A portion of the pad is inserted inside the distal hole, while another portion of the pad is wound about the outer wall to delimit the portion of the pad inside the distal hole of the base. According to the second version, the liquid applicator comprises at least one ventilation element configured to supply air into the receiver and discharge it from there. A liquid application system comprises the liquid package, and the aforesaid applicator. The package comprises the first and second opposite sides of the package forming a hermetically sealed liquid space in between, and a fragile section. The fragile section is configured to be ruptured under the force applied to the package to remove the liquid from the package. The system possesses the property of collapse enabling the first side of the package to be transformed from an arch position into a dish position, when the package is compressed to collapse the previously hermetically sealed space almost completely. The method for applying the liquid on the surface involves applying pressure to the elastic outer surface of the handle on the proximal end of the applicator and pressing the liquid-filled package inside the handle, thereby compressing the elastic portion of the package and rupturing the fragile section of the package for the package bleeding; enabling the liquid flowing through the handle through the distal hole at the base on the distal end of the applicator to the applicator pad attached to the base; and contacting the applicator pad to the surface for the liquid transfer from the applicator pad to the surface.
EFFECT: invention provides time- and quantity-accurate delivery of the required preparation.
63 cl, 12 dwg
SUBSTANCE: invention refers to medical equipment, namely to liquid application devices. A liquid application device comprises a long hollow body having a proximal end and a distal end; an application pad placed on the distal end of the hollow body; and a driven sleeve inserted into the hollow body. The driven sleeve comprises at least one long projection directed towards the distal end. When the driven sleeve moves towards the distal end inside the hollow body, at least one long projection acts from the distal end on a cap of the liquid container to detach the cap towards the distal end from a main body of the liquid container, and thereby providing a liquid release from the container into the application pad. The liquid container is integrated into the hollow body so that the cap is provided from the distal end, and besides prevents the liquid container from displacement both towards the distal end, and round a circle. The liquid application system comprises the above application device, as well as the liquid container integrated into the hollow body of the application device. The liquid container has an outer projection on the main body of the liquid container and is integrated into the hollow body with the outer projection seating between ribs provided on an outer surface of the long hollow body so that the cap is found from the distal end, and besides prevents the liquid container from displacing towards the distal end and in radial direction. The liquid container has radially directed projecting elements and is configured so that displacing the driven sleeve toward the distal end inside the hollow body; at least one long projection acts from the distal end on the radially directed projecting elements of the cap to separate the cap towards the distal end from the main body of the liquid container, and thereby providing the liquid release into the application pad.
EFFECT: developing the liquid application device.
43 cl, 17 dwg
SUBSTANCE: group of inventions relates to medical equipment. Device 20 for local distribution of powder contains reservoir 31 for powder or is made with possibility of connection with it during application, gas flow generator, made with possibility of providing gas flowing through device 20 during application. Device 20 contains mixing device, made with possibility of mechanical shaking reservoir 31. Gas flow generator and mixing device are functionally connected during application in such a way that bringing into action gas flow generator provides gas flowing through device 20, capture of powder from reservoir 31 and distribution of powder from device 20 with simultaneous bringing into action mixing device with mechanical shaking of reservoir 31 and facilitation of release of powder from reservoir 31. Mixing device is made with possibility of bringing into action by gas flow in such a way that mixing device acts when gas is flowing and stops acting when gas flow stops. Mixing device contains mobile element, located on gas flow trajectory. Disclosed is method of haemostatic composition delivery during surgical procedures or after traumatic injury with device application.
EFFECT: providing simple and cheap delivery of drug into specified location.
18 cl, 14 dwg
SUBSTANCE: apparatus has a hollow housing with an opening in form of a spout in which is inserted a porous rod which is directed by one end into the cavity of the housing and protrudes outside by the other end, an adapter which tightly grips the porous rod, and a sealing cap which is in contact with part of the housing in which the porous rod is inserted. The apparatus is further provided with a bushing which is fitted in the spout of the housing between inner surface of the spout and the adapter, and has a flanged edge which rests on the top end of the spout of the housing, and the sealing cap has a stepped inner surface, wherein the steps of the inner surface are horizontal and are provided with an annular protrusion designed to be mated with the top end of the surface of the flanged edge of the bushing. The diameter of the lower part of the inner surface of the sealing cap mated with the outer surface of the spout of the housing is greater than the diameter of the top part on the width of the steps, and the outer diameter of flanged edge of the bushing is not greater than the outer diameter of the spout of the housing. The top part of the bushing is cylindrical and the lower part of the bushing is in form of a truncated cone, wherein the outer diameter of the top part of the bushing matches the inner diameter of the spout of the housing, and the inner diameter of the lower part of the bushing is not greater than the outer diameter of the adapter. In the top part of the outer surface of the housing at the base of the spout, there is an annular ledge with a horizontal top part designed to support the lower end of the sealing cap.
EFFECT: disclosed apparatus has higher air-tightness, enables to determine the presence of a preparation therein, enables easier removal of the sealing cap, is easy to manufacture and assemble.
17 cl, 3 dwg
SUBSTANCE: experimental wound is cleaned daily, first with normal saline (NaCl), and then coated with modified montmorillonite clay containing 0.1 to 4.35 wt % of silver. The preparation is introduced into the wound in an amount of 0.1 g per a wound of 1.5 cm in diameter.
EFFECT: higher rate of septic wound healing.
3 tbl, 3 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutics. Gel form of azelaic acid is described. Gel form includes micronized azelaic acid and additional substances: benzoic acid, disodium edetate, carbomer Carbopol 980, propylene glycol, sodium hydroxide, glycoceramides purified, isopropylmiristate, polysorbate 20, purified water.
EFFECT: invention is provided by obtaining stable medication in form of gel, which does not produce local irritating action in case of long-term on-skin applications.
11 cl, 15 dwg, 5 tbl